Tharimmune, Inc.

Equities

THAR

US4327053090

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-14 pm EDT			5-day change	1st Jan Change
3.35 ^USD	+0.30%		-35.58%	-56.12%

Jun. 10	Tharimmune, Inc. Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis	CI
May. 25	Certain Warrants of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.	CI

Tharimmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 23, 2024 at 08:31 am EST

Tharimmune, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 9.32 million compared to USD 8.47 million a year ago. Basic loss per share from continuing operations was USD 107.0999 compared to USD 280.7999 a year ago.

Latest news about Tharimmune, Inc.

Tharimmune, Inc. Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis	Jun. 10	CI
Certain Warrants of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.	May. 24	CI
Certain Options of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.	May. 24	CI
Certain Common Stock of Tharimmune, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024.	May. 24	CI
Tharimmune to Implement 1-for-15 Reverse Stock Split	May. 22	MT
Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Tharimmune, Inc. Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates	Apr. 23	CI
Tharimmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate	Feb. 20	CI
Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis	Feb. 05	CI
Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104	Jan. 29	CI
Tharimmune Sees 'Positive' Data With TH104 for Pruritus in Chronic Liver Disease	Dec. 11	MT
Tharimmune, Inc. Announces Positive Topline Data with Th104, Its Lead Candidate for Moderate-To-Severe Pruritus in Chronic Liver Disease Patients	Dec. 11	CI
Sector Update: Health Care Stocks Retreat in Late Afternoon	Nov. 28	MT
Top Midday Decliners	Nov. 28	MT
Traders Await Economic Data as US Equity Futures Post Narrow Losses Pre-Bell	Nov. 28	MT
Top Premarket Decliners	Nov. 28	MT
Tharimmune Prices $10 Million Public Share Offering	Nov. 28	MT
Tharimmune Reports Positive Phase 1 Data on Th104, Its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis	Nov. 27	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	Nov. 17	MT
Sector Update: Health Care Stocks Softer Friday Afternoon	Nov. 17	MT
Tharimmune to Implement 1-for-25 Reverse Stock Split	Nov. 17	MT
Tharimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Tharimmune, Inc. Announces Execution of an Exclusive Worldwide Licensing Agreement with Avior Inc. D/B/A Avior Bio, Llc ("Avior") to Develop, Market and Commercialize A Clinical-Stage Asset, Av104 (To Be Renamed Th104 and Hereinafter Referred to as Th104)	Nov. 06	CI
Certain Warrants of Hillstream BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 24-OCT-2023.	23-10-23	CI

Chart Tharimmune, Inc.

Duration

Period

More charts

Company Profile

Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.35 USD

Average target price

75 USD

Spread / Average Target

+2,138.80%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
THARIMMUNE, INC.	-56.12%	2.63M
VERTEX PHARMACEUTICALS INCORPORATED	+18.15%	124B
REGENERON PHARMACEUTICALS, INC.	+18.02%	112B
ARGENX SE	+5.07%	22.94B
BIONTECH SE	-12.75%	22.22B
BEIGENE, LTD.	-9.86%	17.02B
GENMAB A/S	-14.97%	16.88B
WUXI APPTEC CO., LTD.	-39.94%	16.87B
NEUROCRINE BIOSCIENCES, INC.	+2.80%	13.63B
SAREPTA THERAPEUTICS, INC.	+27.39%	11.61B

Bio Therapeutic Drugs